ERBB2 and metastatic melanoma: Our targeted approach has previously associated mRNA expression levels of a subset of genes (including RTKs, PGFRB, EGFR, and ERBB2) with survival in a real-life cohort of BRAFi-treated metastatic melanoma patients, highlighting a tumor proliferation/metabolic rate that might render it more sensitive to BRAFi [23].